peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

D-retro-inverso peptide / senolytic

FOXO4-DRI

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

FOXO4-DRI is described as a senolytic agent (i.e., an agent intended to eliminate senescent cells).

Sources for this introduction: [1]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

FOXO4-DRI is described as a senolytic agent (i.e., an agent intended to eliminate senescent cells).

Sources[1]pubmedAcylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence.FOXO4-DRI, a senolytic agent
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “FOXO4-DRI, a senolytic agent”

    Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence. · Abstract

    pubmed:42391447:9dafc0ede79c:9dafc0ede79c

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
  • 18 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (14), assurance_score_below_0.72 (4), current_regulatory_source_required (3), extraction_ambiguity (18), high_risk_requires_regulatory_or_two_independent_sources (4), no_direct_support (18)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence. ↗

    pubmed · published 2026-09-01 · retrieved 2026-08-26T20:13:52Z

Publication history and provenance

Version 3 · Automated assessment · 2026-08-26T20:13:52Z

b284559fdf0b4a4089f02d6a8293bc1955fd569918502f52250f1232047cc128